University of Vermont Cancer Center Member Profile

    Steven Ades, MD

    Professor, Medicine-Hematology Oncology
    Director, Clinical Trial Office

    Full Member
    Cancer Host and Environment (CHE)
    Academic Interests
    My research focuses on multiple dimensions of supportive care for patients with cancer including improving the identification of cancer patients who are at the highest risk of developing deep venous clots or pulmonary embolism and how to prevent these complications from occurring. Clinically, I subspecialize in gastrointestinal and genitourinary cancer and have led or participated in clinical research programs within those disease site trans-disciplinary teams since joining the UVM Cancer Center in 2007.



    Postdoctoral Training
    2002-2005..... Masters Degree in Epidemiology and Biostatistics, McGill University, Montreal, QC
    2000-2002..... Research Fellow, Center for Adaptation Genetics and Drug Resistance, Tufts University School of Medicine, Boston, MA
    1999-2002..... Hematology/Oncology Fellowship, Tufts University, Boston MA
    1996-1999..... Queens University postgraduate education in Internal Medicine (Kingston, Ontario)


    Education
    1992-1996..... McGill University, Montreal, Canada; MD Medicine
    1989-1992..... McGill University, Montreal Canada; BS Chemistry


    Publications
    To view more and/or the most recent publications by Steven Ades please visit their biblography here.

    Higgins LM, Lester-Coll NH, Ades S, Barry MM, Borrazzo EC, Ganguly EK, Anker CJ.
    'CROSS'-ing into the 'Real World': a retrospective cohort study of patients receiving
    trimodality and bimodality therapy for esophageal cancer. J Gastrointest Oncol. 2023 Apr 29;14(2):480-493. PMID: 37201058

    Ades S, Holmes CE. Implementing guidelines to prevent cancer associated thrombosis: how can we do better? Res Pract Thromb Haemost. 2023 Jan 10;7(1). PMID: 36852109

    Stapleton RD, Ford DW, Sterba KR, Nadig NR, Ades S, Back AL, Carson SS, Cheung KL, Ely J, Kross EK, Macauley RC, Maguire JM, Marcy TW, McEntee JJ, Menon PR, Overstreet A, Ritchie CS, Wendlandt B, Ardren SS, Balassone M, Burns S, Choudhury S, Diehl S, McCown E, Nielsen EL, Paul SR, Rice C, Taylor KK, Engelberg RA. Evolution of Investigating Informed Assent Discussions about CPR in Seriously Ill Patients. J Pain Symptom Manage. 2022 Jun; 63(6):e621-e632. PMID: 35595375

    Ades S, Pulluri B, Holmes C, Lal I, Kumar S, Littenberg B. Risk factors for venous
    thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER-Medicare analysis. Cancer Medicine. 2022. 11(8): 1817-26

    Anker CJ, Lester-Coll NH, Akselrod D, Cataldo PA, Ades S. The Potential for
    Overtreatment with Total Neoadjuvant Therapy (TNT): Consider One Local Therapy
    Instead. Clinical Colorectal Cancer. 2022

    Anker CJ, Akselrod D, Ades S, Bianchi NA, Lester-Coll NH, Cataldo PA. Non-Operative
    Management (NOM) of Rectal Cancer: Literature Review & Translating Evidence into
    Practice. Current Colorectal Cancer Reports. 2021;17(1):23–41.

    Ades S, Adrianzen Herrera D, Lahey T, Thomas AA, Jasra S, Barry M, Sprague J, Dittus, Plante TB, Kelly J, Kaufman PA, Khan F, Hammond CJ, Gernander K, Parsons P, Holmes C. Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect. JCO Oncology Practice. 2021. Accepted on July 2, 2021 and published at ascopubs.org/journal/op on August 2, 2021: DOI https://doi.org/10. 1200/OP.21.00116

    Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open, 2021;4(1):e2033787. doi:10.1001. PMID 2774904